What Is Glutathione

Glutathione is a tripeptide molecule composed of the amino acids cysteine, glutamate, and glycine. It functions as the body's primary intracellular antioxidant, playing central roles in neutralizing reactive oxygen species, recycling other antioxidants like vitamins C and E, and conjugating toxins for elimination. Every human cell produces glutathione, with especially high concentrations found in the liver, lungs, and kidneys.

Aging is associated with a progressive decline in glutathione levels across multiple tissues. This decline correlates with increased oxidative damage to DNA, proteins, and lipid membranes, all of which contribute to the functional deterioration of cells and organs over time. Because glutathione sits at the intersection of antioxidant defense, detoxification, and immune regulation, its depletion does not merely reflect aging; it participates in driving the process forward. Lower glutathione status has been observed in conditions commonly associated with accelerated aging, including neurodegenerative disease, cardiovascular disease, type 2 diabetes, and chronic lung disease.

The longevity relevance extends beyond passive defense. Glutathione directly participates in phase II liver detoxification, where it conjugates with fat-soluble toxins, heavy metals, and metabolic byproducts to render them water-soluble for excretion. In an era of increasing environmental chemical exposure, the capacity of this conjugation pathway influences how effectively the body clears accumulated toxic burden. Glutathione also modulates immune cell function: T-cells, natural killer cells, and macrophages all require adequate intracellular glutathione to proliferate and function normally.

Glutathione exists in two forms inside cells: reduced (GSH) and oxidized (GSSG). The reduced form is the active antioxidant. When GSH encounters a reactive oxygen species or a free radical, it donates an electron, neutralizing the threat while itself becoming oxidized to GSSG. The enzyme glutathione reductase, using NADPH as a cofactor, then recycles GSSG back to GSH. The ratio of GSH to GSSG in a cell is one of the most reliable indicators of that cell's redox health; a falling ratio signals oxidative stress.

In detoxification, glutathione S-transferase (GST) enzymes attach GSH to a wide range of electrophilic compounds, including environmental pollutants, drug metabolites, and endogenous waste products. This conjugation makes the compounds more water-soluble and tags them for export from the cell and eventual excretion through bile or urine. Genetic variations in GST enzymes (GSTM1, GSTT1, GSTP1) affect the efficiency of this pathway, which is one reason identical toxic exposures can produce very different health outcomes across individuals.

Glutathione also supports the function of other antioxidant systems. After vitamin C donates an electron to neutralize a radical, it becomes oxidized (dehydroascorbate). Glutathione reduces it back to its active form. A similar recycling relationship exists with vitamin E in lipid membranes. This places glutathione at the hub of the entire antioxidant network rather than being simply one member of it. Additionally, glutathione peroxidase enzymes, a family of selenoproteins, use GSH specifically to reduce hydrogen peroxide and lipid hydroperoxides, protecting cell membranes and mitochondrial structures from oxidative degradation.

Glutathione is available in several forms, each with distinct absorption characteristics. Reduced glutathione (GSH) in standard capsules or tablets is subject to extensive degradation by digestive enzymes and intestinal peptidases, which limits how much reaches the bloodstream intact. Liposomal glutathione wraps the molecule in phospholipid spheres, protecting it from digestive breakdown and facilitating absorption through intestinal cell membranes. This form has shown measurably higher bioavailability in small clinical comparisons against unformulated oral glutathione.

S-acetyl glutathione is another oral option in which an acetyl group shields the sulfhydryl group during digestion, with deacetylation occurring intracellularly. Evidence for this form is less extensive but suggests improved stability. Sublingual and buccal delivery systems aim to bypass first-pass metabolism by absorbing through the oral mucosa. Intravenous glutathione achieves the highest immediate plasma levels but requires clinical administration, is short-lived in circulation, and must be repeated frequently to maintain elevation.

Precursor-based strategies represent an indirect but well-validated delivery approach. NAC provides cysteine, typically the rate-limiting amino acid for glutathione synthesis. Glycine supplementation addresses a second precursor bottleneck, particularly relevant in older adults. Whey protein, rich in cysteine-containing peptides, has also been shown to raise glutathione levels in clinical settings.

Dosing depends on the form and the intent. For liposomal glutathione, common oral doses range from 250 to 1,000 mg per day, typically divided into one or two doses. Clinical studies showing increased blood glutathione levels have generally used the 500 to 1,000 mg range. For NAC as a precursor strategy, 600 to 1,800 mg per day in divided doses is standard, with most research using 600 mg twice daily. GlyNAC protocols in clinical trials have used approximately 100 mg per kilogram of body weight per day of each component (glycine and NAC), though lower doses may be sufficient for maintenance.

IV glutathione is typically administered at 600 to 2,000 mg per session, often as part of a broader IV nutrient protocol. Sessions are usually weekly or biweekly, though no standardized clinical protocol exists for frequency or duration. Individual response varies considerably, influenced by baseline glutathione status, genetic factors affecting GST enzyme efficiency, concurrent toxic exposures, and the overall demand the body places on its detoxification systems. Starting at the lower end of any dosing range and adjusting based on clinical response and, where available, lab monitoring is a reasonable approach.

For liposomal glutathione, the quality of the liposomal encapsulation is the most critical variable. Look for products that specify the type of phospholipid used (phosphatidylcholine from sunflower or soy lecithin is standard), the particle size of the liposomes, and whether the product uses the reduced (GSH) form. Some manufacturers provide third-party verification of liposomal integrity and glutathione content through independent lab testing.

For NAC supplements, the reduced form (N-acetyl-L-cysteine) should be clearly stated. Certificates of analysis from third-party testing organizations such as NSF International, USP, or independent labs help verify that the product contains what is listed on the label and is free of contaminants. Products stored in light-protective packaging are preferable, as glutathione and its precursors can degrade with light and heat exposure. For IV formulations, sterile, preservative-free glutathione from a compounding pharmacy that follows USP 797 or 800 standards is the baseline expectation. Any sulfurous or off smell in oral glutathione supplements may indicate oxidation, which reduces efficacy.

The basic biochemistry of glutathione is well established and uncontroversial; it is one of the most studied molecules in redox biology. Observational research consistently links lower glutathione levels with aging, chronic disease states, and increased mortality risk in older populations. Intervention studies using NAC as a glutathione precursor have shown measurable increases in blood and tissue glutathione levels in both younger and older adults, with one notable clinical trial in older adults demonstrating that combined glycine and NAC supplementation (GlyNAC) raised glutathione, reduced oxidative stress markers, and improved several age-related functional measures.

Direct glutathione supplementation is less extensively studied. Small trials of liposomal glutathione have shown increased blood glutathione levels compared to placebo, though the clinical significance of these increases for long-term health outcomes remains unclear. IV glutathione has been studied in Parkinson's disease, with mixed and mostly inconclusive results across small trials. The evidence for specific disease prevention through glutathione supplementation alone is not sufficient to draw firm conclusions, in part because most trials are small, short in duration, and use heterogeneous formulations. The precursor approach (NAC, glycine, whey protein) has a stronger and more consistent evidence base than direct oral glutathione for raising intracellular levels.

Glutathione supplementation is generally well tolerated at typical oral and IV doses. Gastrointestinal discomfort is the most commonly reported side effect of oral forms. High-dose IV glutathione can occasionally cause cramping or bloating. There is a theoretical concern that large doses of any antioxidant could interfere with oxidative-stress-dependent cancer therapies, so individuals undergoing chemotherapy or radiation should discuss timing and dosing with their treatment team. NAC, the most common precursor supplement, has a strong safety record but can cause nausea at higher doses and may interact with nitroglycerin and certain other medications.